Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Human Microbiome Market, by Product
1.4.2 Europe Human Microbiome Market, by Disease Type
1.4.3 Europe Human Microbiome Market, by Technology
1.4.4 Europe Human Microbiome Market, by Application
1.4.5 Europe Human Microbiome Market, by Type
1.4.6 Europe Human Microbiome Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Human Microbiome Market by Product
3.1 Europe Drugs Market by Country
3.2 Europe Diagnostic Tests Market by Country
3.3 Europe Probiotics Market by Country
3.4 Europe Prebiotics Market by Country
3.5 Europe Others Market by Country
Chapter 4. Europe Human Microbiome Market by Disease Type
4.1 Europe Infectious Diseases Market by Country
4.2 Europe Endocrine & Metabolic Disorders Market by Country
4.3 Europe Gastrointestinal Diseases Market by Country
4.4 Europe Cancer Market by Country
4.5 Europe Others Market by Country
Chapter 5. Europe Human Microbiome Market by Technology
5.1 Europe Genomics Market by Country
5.2 Europe Proteomics Market by Country
5.3 Europe Metabolomics Market by Country
Chapter 6. Europe Human Microbiome Market by Application
6.1 Europe Therapeutics Market by Country
6.2 Europe Diagnostics Market by Country
Chapter 7. Europe Human Microbiome Market by Type
7.1 Europe Microbiome Consortia Transplantation (FMT) Market by Country
7.2 Europe Peptide Market by Country
7.3 Europe Live Biotherapeutic Product Market by Country
7.4 Europe Others Market by Country
Chapter 8. Europe Human Microbiome Market by Country
8.1 Germany Human Microbiome Market
8.1.1 Germany Human Microbiome Market by Product
8.1.2 Germany Human Microbiome Market by Disease Type
8.1.3 Germany Human Microbiome Market by Technology
8.1.4 Germany Human Microbiome Market by Application
8.1.5 Germany Human Microbiome Market by Type
8.2 UK Human Microbiome Market
8.2.1 UK Human Microbiome Market by Product
8.2.2 UK Human Microbiome Market by Disease Type
8.2.3 UK Human Microbiome Market by Technology
8.2.4 UK Human Microbiome Market by Application
8.2.5 UK Human Microbiome Market by Type
8.3 France Human Microbiome Market
8.3.1 France Human Microbiome Market by Product
8.3.2 France Human Microbiome Market by Disease Type
8.3.3 France Human Microbiome Market by Technology
8.3.4 France Human Microbiome Market by Application
8.3.5 France Human Microbiome Market by Type
8.4 Russia Human Microbiome Market
8.4.1 Russia Human Microbiome Market by Product
8.4.2 Russia Human Microbiome Market by Disease Type
8.4.3 Russia Human Microbiome Market by Technology
8.4.4 Russia Human Microbiome Market by Application
8.4.5 Russia Human Microbiome Market by Type
8.5 Spain Human Microbiome Market
8.5.1 Spain Human Microbiome Market by Product
8.5.2 Spain Human Microbiome Market by Disease Type
8.5.3 Spain Human Microbiome Market by Technology
8.5.4 Spain Human Microbiome Market by Application
8.5.5 Spain Human Microbiome Market by Type
8.6 Italy Human Microbiome Market
8.6.1 Italy Human Microbiome Market by Product
8.6.2 Italy Human Microbiome Market by Disease Type
8.6.3 Italy Human Microbiome Market by Technology
8.6.4 Italy Human Microbiome Market by Application
8.6.5 Italy Human Microbiome Market by Type
8.7 Rest of Europe Human Microbiome Market
8.7.1 Rest of Europe Human Microbiome Market by Product
8.7.2 Rest of Europe Human Microbiome Market by Disease Type
8.7.3 Rest of Europe Human Microbiome Market by Technology
8.7.4 Rest of Europe Human Microbiome Market by Application
8.7.5 Rest of Europe Human Microbiome Market by Type
Chapter 9. Company Profiles
9.1 Ferring Holdings SA
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research and Development Expense
9.1.5 Recent Strategies and Developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.2 Enterome
9.2.1 Company Overview
9.2.2 Recent Strategies and Developments:
9.2.2.1 Partnerships, Collaborations, and Agreements:
9.3 Seres Therapeutics, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Research & Development Expense
9.3.4 Recent Strategies and Developments:
9.3.4.1 Partnerships, Collaborations, and Agreements:
9.4 4D Pharma Plc
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 Recent Strategies and Developments:
9.4.4.1 Partnerships, Collaborations, and Agreements:
9.5 OptiBiotix Health Plc
9.5.1 Company Overview
9.6 Synlogic, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expense
9.7 Second Genome, Inc.
9.7.1 Company Overview
9.8 Vedanta Biosciences, Inc.
9.8.1 Company Overview
9.9 Finch Therapeutics Group, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expense
Unique Offerings 